Table 4.

EV mimetics and their therapeutic applications

EV mimetics	Therapeutic applications	Reference
Cell-derived nanovesicles	Possess similar physical character, protein, and lipid content to exosomes and successfully distributed to the tumor site in a mouse cancer model	(Goh et al., 2017b)
Cell-derived nanovesicles	Prevent emphysema mainly via an FGF2-dependent pathway	(Kim et al., 2017b)
Cell-derived nanovesicles loaded with doxorubicin	Deliver doxorubicin preferentially to cancerous cells over healthy cells	(Goh et al., 2017a)
EV-mimetic nanovesicles	Promote hepatocyte proliferation and liver regeneration by boosting the sphingosine kinase 2 levels in recipient cells	(Wu et al., 2018)
EV-mimetic nanovesicles loaded with doxorubicin	Reduce tumor growth without the adverse effects observed with equipotent free drug	(Jang et al., 2013)
EV-mimetic nanovesicles loaded with lncRNA-H19	Neutralize the regeneration-inhibiting effect of hyperglycemia, and could remarkably accelerate the healing processes of chronic diabetic wounds	(Tao et al., 2018)
EV-mimetic nanovesicles loaded with RNAi	Target c-Myc in cancer	(Lunavat et al., 2016)